Biological Evaluation of New Erlotinib Derivatives in the EGFR-Positive MCF-۷ Breast Cancer Model

Erlotinib, an EGFR-targeted tyrosine kinase inhibitor, has established benefit in select malignancies. In this work, we profiled nine newly prepared erlotinib derivatives against the MCF-۷ Breast cancer line using dose-response MTT assays. Derivative ۱۴ emerged as the most active candidate, achieving an IC۵۰ of ۹.۹۰ uM. Flow-cytometric cell-cycle analysis revealed a consistent G۰/G۱ blockade across the panel, aligning with reduced proliferation. Programmed cell death was further substantiated by Annexin V/PI staining and the microscopic detection of apoptotic bodies. Taken together, these data indicate that erlotinib-derived compounds suppress MCF-۷ growth through dual mechanisms, cell-cycle arrest and apoptosis-and underscore their potential as promising targeted leads for Breast cancer therapy. Data from unpublished work - presented with permission; chemical structures not disclosed pending publication.

کلیدواژه ها:

Tyrosine kinase inhibitor ، Apoptosis ، Erlotinib